Aciraft-LS Capsules

Aciraft-LS Capsules are a combination therapy containing Rabeprazole Sodium (Enteric Coated) 20 mg and Levosulpiride (Sustained Release) 75 mg. This dual-action formulation is designed to manage acid-related disorders associated with impaired gastric motility.

Rabeprazole Sodium is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H⁺/K⁺-ATPase enzyme system in gastric parietal cells. It effectively reduces acidity, promotes ulcer healing, and relieves acid reflux symptoms.
Levosulpiride is a prokinetic agent that improves gastrointestinal motility, enhances gastric emptying, and reduces symptoms such as bloating, nausea, and early satiety.

The enteric-coated and sustained-release formulation ensures targeted drug release, prolonged action, and improved patient compliance. Aciraft-LS is commonly prescribed in gastro-esophageal reflux disease (GERD) with dyspepsia, functional dyspepsia, and acid reflux associated with delayed gastric emptying.

Composition
Each hard gelatin capsule contains:
Rabeprazole Sodium IP 20 mg (as enteric-coated pellets)
Levosulpiride IP 75 mg (as sustained-release pellets)
Excipients q.s.

Indications
Gastro-esophageal reflux disease (GERD)
Functional dyspepsia
Acid reflux with bloating and nausea
Delayed gastric emptying

Key Benefits
Dual action: acid suppression + prokinetic effect
Improves gastric motility and digestion
Long-lasting relief from reflux and dyspepsia
Enteric-coated and sustained-release formulation

Dosage and Administration
As directed by the physician. Capsules should be swallowed whole and not opened, crushed, or chewed.

Storage
Store in a cool, dark, and dry place. Protect from light.
Keep out of reach of children.

Regulatory Information
Schedule H prescription drug. To be sold by retail on the prescription of a Registered Medical Practitioner only.